Dr. Ross C. Donehower, MD

Dr. Donehower practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Donehower's NPI, 1780631713, was assigned on May 27, 2006. Dr. Donehower graduated from University of Minnesota Medical School in 1974. Dr. Donehower holds Maryland license D23675.

Dr. Donehower's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Donehower's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Donehower is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Donehower to 1 more hospice, 1 ambulatory surgery center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Donehower practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Donehower's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Donehower is licensed in Maryland.

CMS data shows 313 Medicare services from Dr. Donehower across 6 procedure codes in 2024, for 143 Medicare patients. Medicare paid $26,348 for them.

CMS counts 143 Medicare patients who saw Dr. Donehower in 2024. The largest group is 65 to 74, with 69 patients. 75% of them have high blood pressure, and 68% have cancer. 13% are also on Medicaid. Their average risk score is 2.38, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Donehower's median patient age at 72, with 52% women.

In 2024, Dr. Donehower wrote 111 Medicare Part D claims for 22 patients. 73% of them were for generic drugs. CMS names the drug for 27 of them, across 2 drugs with 11 or more claims each, at $7,485 in total drug cost. In 2023, CMS named 47 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Donehower for performance year 2024, reported as part of a group. CMS lists Dr. Donehower as offering telehealth.

Dmand AI links 31 papers to Dr. Donehower, published from 2010 to 2021. 2011 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized and Colorectal Neoplasms. Dr. Donehower has published most often in Cancer Med. Dr. Donehower's most frequent co-authors are Daniel Alexander Laheru, MD, Lei Zheng, MD and Christopher Wolfgang, MD, PhD.

Dmand AI links Dr. Donehower to 1 clinical trial. Conditions studied include Pancreatic Neoplasms and Pancreatic Diseases.

CMS Open Payments shows 3 general payments to Dr. Donehower from 1 drug or device company from 2016 to 2017. Consulting fees make up the largest share, 100% of the total. Genentech, Inc. paid the most, $6,660.

Dr. Donehower graduated from University of Minnesota Medical School in 1974.